AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Natera to Present 12 Datasets Featuring Over 50,000 Patients at SABCS 2025
ByAinvest
Tuesday, Dec 2, 2025 8:12 am ET1min read
Natera will present 12 abstracts at the San Antonio Breast Cancer Symposium featuring data from over 50,000 patients using Signatera, a genome-based test for breast cancer recurrence. The data demonstrates 100% sensitivity and specificity in detecting breast cancer recurrence in the surveillance setting, with patients who tested positive for Signatera at any time post-treatment associated with worse distant recurrence-free survival. The presentations showcase the prognostic and predictive power of Signatera across diverse breast cancer subtypes and settings.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet